Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma

This study has been completed.
Information provided by (Responsible Party):
National Cancer Institute (NCI) Identifier:
First received: October 18, 2006
Last updated: December 3, 2015
Last verified: May 2013
This phase II trial is studying how well ziv-aflibercept works in treating patients with locally advanced, unresectable or metastatic gynecologic soft tissue sarcoma. Ziv-aflibercept may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Condition Intervention Phase
Fallopian Tube Cancer
Female Reproductive Cancer
Ovarian Carcinosarcoma
Ovarian Sarcoma
Recurrent Ovarian Epithelial Cancer
Recurrent Uterine Sarcoma
Stage III Ovarian Epithelial Cancer
Stage III Uterine Sarcoma
Stage IV Ovarian Epithelial Cancer
Stage IV Uterine Sarcoma
Uterine Carcinosarcoma
Uterine Leiomyosarcoma
Drug: ziv-aflibercept
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study of VEGF-Trap in Recurrent or Metastatic Gynecologic Soft-Tissue Sarcomas

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Objective Response Rate, Evaluated According to the RECIST Criteria [ Time Frame: Up to 3 years ]
  • Incidence of Disease Stabilization, as Measured by Progression-free Survival at 6 Months (Leiomyosaroma Group) [ Time Frame: 6 months ]
  • Incidence of Disease Stabilization, as Measured by Progression-free Survival at 6 Months (Carcinosarcoma Group) [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • Survival (Leiomyosarcoma Group) [ Time Frame: Up to 3 years ]
    Survival statistics will be estimated using the Kaplan-Meier method. Standard descriptive statistics, such as the mean, median, range and proportion, will be used to summarize the patient sample and to estimate parameters of interest. 95% confidence intervals will be provided for estimates of interest where possible.

  • Survival (Carcinosarcoma Group) [ Time Frame: Up to 3 years ]
    Survival statistics will be estimated using the Kaplan-Meier method. Standard descriptive statistics, such as the mean, median, range and proportion, will be used to summarize the patient sample and to estimate parameters of interest. 95% confidence intervals will be provided for estimates of interest where possible.

Enrollment: 63
Study Start Date: September 2006
Study Completion Date: August 2013
Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment (ziv-aflibercept)
Patients receive ziv-aflibercept IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
Drug: ziv-aflibercept
Given IV
Other Names:
  • aflibercept
  • vascular endothelial growth factor trap
  • VEGF Trap
  • Zaltrap

Detailed Description:


I. To assess the objective response of recurrent or metastatic gynecologic soft-tissue sarcomas to VEGF-Trap (ziv-aflibercept).

II. To assess the incidence of disease stabilization, as measured by 6-month progression-free survival, in patients with recurrent or metastatic gynecologic soft-tissue sarcomas treated with VEGF-Trap.


I. To assess time-to-progression and overall survival in patients with recurrent or metastatic gynecologic soft-tissue sarcoma treated with VEGF-Trap.

* As of 24 October 2012, overall survival follow-up is to be discontinued for the one remaining patient on long term follow-up, who has been off protocol therapy for at least 3 years. Time to progression and median survival times have been based on the currently available data.

II. To assess the toxicity associated with VEGF-Trap in patients with recurrent or metastatic gynecologic soft-tissue sarcoma.

III. To characterize the population pharmacokinetics of VEGF-Trap and to explore for demographic and clinical covariates

OUTLINE: This is an open-label, multicenter study.

Patients are stratified according to histology (uterine leiomyosarcoma vs malignant mixed mullerian tumor/carcinosarcoma). Patients receive ziv-aflibercept over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood collection at baseline, every 8 weeks during treatment, and 60 days after completion of study treatment for population pharmacokinetic analysis using enzyme-linked immunosorbent assay (ELISA).

After completion of study treatment, patients are followed at 4 weeks and then every 3 months thereafter.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically/cytologically confirmed soft tissue sarcoma of gynecologic tract including 1 of the following subtypes: uterine leiomyosarcoma, malignant mixed mullerian tumor/carcinosarcoma, disease originating in ovary/fallopian tube allowed
  • Locally advanced/unresectable/metastatic disease
  • Previously treated disease must have radiographic/clinical evidence of PD
  • Measurable disease-at least 1 lesion in at least 1 dimension (longest diameter) as >=20mm with conventional techniques or as >=10mm with spiral CT scan
  • Indicator lesions may not have been previously treated with surgery/radiotherapy/radiofrequency ablation unless PD has been confirmed
  • ECOG PS 0-2 OR Karnofsky PS 60-100%
  • Life expectancy>=3 months
  • WBC>=3,000/mm^3
  • Absolute neutrophil count>=1,500/mm^3
  • Platelet count>=75,000/mm^3
  • Bilirubin=<1.5xULN
  • AST and ALT=<3xULN
  • INR=<1.5 (unless on warfarin)
  • Creatinine=<1.5xULN OR creatinine clearance>=60 mL/min
  • Urine protein<1+ by dipstick OR 24-hour urine protein<500 mg OR urine protein:creatinine ratio<1
  • Not pregnant/nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for ≥6 months after treatment - No other active malignancy within past 5 years except adequately treated cervical carcinoma in situ/nonmelanoma skin cancer
  • No known hypersensitivity to Chinese hamster ovary cell products/other recombinant human antibodies
  • No history of allergic reactions attributed to compounds of similar chemical/biological composition to study agents
  • No serious/nonhealing wound/ulcer/bone fracture
  • No abdominal fistula/gastrointestinal perforation/bowel obstruction/intraabdominal abscess within past 28 days
  • No significant traumatic injuries within past 28 days
  • No evidence of bleeding diathesis/coagulopathy
  • No uncontrolled intercurrent illness including but not limited to: Ongoing/active infection, psychiatric illness or social situations that would preclude study compliance
  • <=2 prior cytotoxic chemotherapy regimen for recurrent, locally advanced or metastatic disease
  • Recovered from prior therapy
  • No prior antiangiogenic agent

Exclusion Criteria:

  • < 4weeks since prior chemotherapy (<6 weeks for nitrosoureas/carmustine/mitomycin C), prior investigational treatment, radiotherapy and major surgery/open biopsy
  • 1 week since prior core biopsy
  • 1 month since prior thrombolytic agents
  • Concurrent full-dose anticoagulants with INR>1.5 allowed if: In-range INR (usually between 2-3) on stable dose of oral anticoagulant or low molecular weight heparin,
  • OR; For patients on warfarin, the upper target for INR is ≤3 No active bleeding/pathological condition that carries a high risk of bleeding (e.g. tumor invading major vessels/known varices)
  • No evidence of CNS disease including primary brain tumor/brain metastasis
  • No other concurrent investigational agents - No concurrent major surgery
  • No concurrent combination antiretroviral therapy for HIV-positive patients
  • Clinically significant cardiovascular disease including:

    • Cerebrovascular accident within past 6 months,
    • Uncontrolled hypertension defined as BP>150/100mmHg OR systolic BP>180mmHg if diastolic BP<90 mmHg, on ≥2 repeated determinations on separate days within past 3 months,
  • OR; Antihypertensive medications allowed as long as dose and number of antihypertensive medications have not increased within past 2 weeks, Myocardial infarction, coronary artery bypass graft, or unstable angina within past 6 months, OR;
  • OR; NYHA class III-IV congestive heart failure, serious cardiac arrhythmia requiring medication, or unstable angina pectoris within past 6 months, Clinically significant peripheral vascular disease within past 6 months
  • OR; pulmonary embolism, deep vein thrombosis, or other thromboembolic event within past 6 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00390234

United States, California
City of Hope
Duarte, California, United States, 91010
University of Southern California
Los Angeles, California, United States, 90033-0804
UC Davis Comprehensive Cancer Center
Sacramento, California, United States, 95817
United States, Illinois
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States, 60637-1470
Evanston CCOP-NorthShore University HealthSystem
Evanston, Illinois, United States, 60201
Peoria Gynecologic Oncology
Peoria, Illinois, United States, 61603
United States, Michigan
University of Michigan University Hospital
Ann Arbor, Michigan, United States, 48109
United States, Pennsylvania
Fox Chase Cancer Center
Rockledge, Pennsylvania, United States, 19046
Canada, British Columbia
Vancouver General Hospital
Vancouver, British Columbia, Canada, V5C 1M9
BCCA-Vancouver Cancer Centre
Vancouver, British Columbia, Canada, V5Z 4E6
Canada, Ontario
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada, L8V 5C2
Cancer Centre of Southeastern Ontario at Kingston General Hospital
Kingston, Ontario, Canada, K7L 5P9
London Regional Cancer Program
London, Ontario, Canada, N6A 4L6
Odette Cancer Centre- Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N 3M5
University Health Network-Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9
Canada, Quebec
McGill University Department of Oncology
Montreal, Quebec, Canada, H2W 1S6
Sponsors and Collaborators
National Cancer Institute (NCI)
Principal Investigator: Amit Oza University Health Network-Princess Margaret Hospital
  More Information

Responsible Party: National Cancer Institute (NCI) Identifier: NCT00390234     History of Changes
Other Study ID Numbers: NCI-2009-00177
PHL-051 ( Other Grant/Funding Number: N01CM62209 )
CDR0000508798 ( Other Grant/Funding Number: N01CM62209 )
N01CM62209 ( US NIH Grant/Contract Award Number )
N01CM62203 ( US NIH Grant/Contract Award Number )
N01CM62201 ( US NIH Grant/Contract Award Number )
Study First Received: October 18, 2006
Results First Received: November 14, 2014
Last Updated: December 3, 2015

Additional relevant MeSH terms:
Neoplasms, Glandular and Epithelial
Ovarian Neoplasms
Fallopian Tube Neoplasms
Mixed Tumor, Mullerian
Uterine Neoplasms
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Fallopian Tube Diseases
Neoplasms, Muscle Tissue
Neoplasms, Complex and Mixed
Uterine Diseases
Endothelial Growth Factors
Growth Substances
Physiological Effects of Drugs processed this record on May 22, 2017